nab-Sirolimus for Patients With Malignant Perivascular Epithelioid Cell Tumors

Home nab-Sirolimus for Patients With Malignant Perivascular Epithelioid Cell Tumors

nab-Sirolimus for Patients With Malignant Perivascular Epithelioid Cell Tumors

/ Publications

Share the Post

About the Author

Related Posts

Analysis of inactivating TSC1 and TSC2 alterations in a real-world patient population with advanced gynecological cancers in the Foundation Medicine genomic database
Aadi Bioscience Closes $23 Million in Series A Funding
Antitumor activity of nab-sirolimus versus mTOR inhibitors temsirolimus, sirolimus, and everolimus in A549 NSCLC xenografts
Evaluation of nab-sirolimus in combination with fulvestrant or PI3K pathway inhibitors to overcome resistance in breast cancer cell lines
Aadi Bioscience Recieves FDA’ Orphan Product Development Grant for Treatment of Advanced PEComa
Aadi Bioscience Announces FDA Approval of its First Product FYARRO™ for Patients with Locally Advanced Unresectable or Metastatic Malignant Perivascular Epithelioid Cell Tumor (PEComa)
Response to Treatment With nab-Sirolimus Among Patients With Primary Uterine PEComa: A Subanalysis From AMPECT
Real-world analysis of patients with advanced gastrointestinal cancers harboring inactivating alterations in TSC1 and TSC2 using the Foundation Medicine genomic database

Comments

Comments are closed.